Stereotaxis to Present at Upcoming Investor Conferences

Rhea-AI Summary

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, has announced its participation in two upcoming investor conferences in New York City this September. CEO David Fischel will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10th, 2025, at 8:00 am EDT, and attend the Lake Street Capital 9th Annual Best Ideas Growth Conference on September 11th, 2025.

The company, which has treated over 150,000 patients globally with its robotic technology, will discuss its technological and commercial progress in its growth strategy. One-on-one meetings with Mr. Fischel can be arranged through conference registration.

ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and CEO, will present at two investor conferences in New York City in September.

• H.C. Wainwright 27th Annual Global Investment Conference
  Mr. Fischel will present an overview of Stereotaxis business on Wednesday, September 10^th, 2025, at 8:00 am EDT and will be available that same day for one-on-one meetings.

• Lake Street Capital 9th Annual Best Ideas Growth Conference
  Mr. Fischel will be available for one-on-one meetings on Thursday, September 11, 2025.

“We are excited to participate in these conferences and look forward to sharing the technological and commercial progress being made in Stereotaxis’ growth strategy,” says Mr. Fischel. One-on-one meetings with Mr. Fischel can be arranged through registration with these conferences.

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934, including statements regarding the completion of the Company’s offering and the anticipated use of proceeds therefrom, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the SEC. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this press release. There can be no assurance that the Company will recognize revenue related to customer purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.

Stereotaxis Contacts:
David L. Fischel
Chairman and Chief Executive Officer

Kimberly Peery
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

FAQ

When is Stereotaxis (STXS) presenting at the H.C. Wainwright Global Investment Conference?

Stereotaxis CEO David Fischel will present on Wednesday, September 10th, 2025, at 8:00 am EDT at the H.C. Wainwright Conference in New York City.

How many patients have been treated with Stereotaxis (STXS) technology?

Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere.

What conferences will Stereotaxis (STXS) attend in September 2025?

Stereotaxis will attend the H.C. Wainwright 27th Annual Global Investment Conference on September 10th and the Lake Street Capital 9th Annual Best Ideas Growth Conference on September 11th.

How can investors meet with Stereotaxis (STXS) CEO David Fischel at the conferences?

Investors can arrange one-on-one meetings with CEO David Fischel through registration with the respective conferences.

What is Stereotaxis (STXS) main business focus?

Stereotaxis is a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, focusing on robotic systems, instruments, and information solutions for the interventional laboratory.